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Boosts Wnt Signaling In Colorectal Cancer Cells 
Abstract 
Colorectal cancer (CRC) is one of the leading causes of deaths in the United States. Roughly 150,000 new 
cases are diagnosed each year, resulting in ~50,000 deaths. About 10-30% of CRC patients harbor either 
loss of or missense mutations in SMAD4, a critical component of the TGF-β signaling pathway. Our lab 
and others have shown that complete loss of Smad4 results in the increase in tumor size, microvascular 
density, and frequency of metastasis in CRC xenograft models. While the role of Smad4 loss in CRC 
progression has been extensively studied, the pathophysiological function of missense mutations in 
Smad4 is not fully understood. At the molecular level, these mutations usually map to the MH2 domain 
and eliminate residues that are involved in the formation of the heteromeric complex with regulatory 
Smads (R-Smads) such as Smad2/3 and ensuing transcriptional activation. These detrimental effects 
suggest that SMAD4 missense mutations can be categorized as loss-of-function (LOF). However, 
uncharacteristically for LOF mutations, they cluster in a few hotspots (e.g., R361), which is more 
consistent with a gain-of- or neomorphic function. Here, we investigated the functional role of Smad4 
R361 mutants in vitro by re-expressing two R361 Smad4 variants in Smad4-null CRC cells. As predicted, 
R361 mutations disrupted Smad2/3-Smad4 heteromeric complex formation and abolished canonical 
TGF-β downstream signaling. In that, they were similar to SMAD4 loss. However, RNA sequencing and 
subsequent RT-PCR revealed that Smad4mut cells possess the known gene signature associated with 
enhanced LEF1 protein function and increased WNT signaling. Mechanistically, Smad4 mutant proteins 
retained binding to LEF1 protein and directed a commensurate increase in downstream Wnt signaling as 
measured by TOP/FOP luciferase assay. Consistent with these findings, human CRCs with SMAD4 
missense mutations were less likely to acquire activating mutations in the key Wnt pathway gene 
CTNNB1 (encoding beta catenin) than CRCs with truncating SMAD4 nonsense mutations. The former was 
also associated with shorter survival. Collectively, these studies implicate a TGF-β ligand-independent 
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SMAD4 WITH R361 HOTSPOT MUTATIONS RETAINS THE ABILITY TO BIND 
TO LEF1 AND BOOSTS WNT SIGNALING IN COLORECTAL CANCER CELLS 
Claudia B Lanauze Torres 
Andrei Thomas-Tikhonenko 
Colorectal cancer (CRC) is one of the leading causes of deaths in the United 
States. Roughly 150,000 new cases are diagnosed each year, resulting in ~50,000 
deaths. About 10-30% of CRC patients harbor either loss of or missense mutations in 
SMAD4, a critical component of the TGF-β signaling pathway. Our lab and others have 
shown that complete loss of Smad4 results in the increase in tumor size, microvascular 
density, and frequency of metastasis in CRC xenograft models. While the role of Smad4 
loss in CRC progression has been extensively studied, the pathophysiological function of 
missense mutations in Smad4 is not fully understood. At the molecular level, these 
mutations usually map to the MH2 domain and eliminate residues that are involved in the 
formation of the heteromeric complex with regulatory Smads (R-Smads) such as Smad2/3 
and ensuing transcriptional activation. These detrimental effects suggest that SMAD4 
missense mutations can be categorized as loss-of-function (LOF). However, 
uncharacteristically for LOF mutations, they cluster in a few hotspots (e.g., R361), which 
is more consistent with a gain-of- or neomorphic function. Here, we investigated the 
functional role of Smad4 R361 mutants in vitro by re-expressing two R361 Smad4 variants 
in Smad4-null CRC cells. As predicted, R361 mutations disrupted Smad2/3-Smad4 
heteromeric complex formation and abolished canonical TGF-β downstream signaling. In 
that, they were similar to SMAD4 loss. However, RNA sequencing and subsequent RT-
PCR revealed that Smad4mut cells possess the known gene signature associated with 
enhanced LEF1 protein function and increased WNT signaling. Mechanistically, Smad4 
vi 
mutant proteins retained binding to LEF1 protein and directed a commensurate increase 
in downstream Wnt signaling as measured by TOP/FOP luciferase assay. Consistent with 
these findings, human CRCs with SMAD4 missense mutations were less likely to acquire 
activating mutations in the key Wnt pathway gene CTNNB1 (encoding β-catenin) than 
CRCs with truncating SMAD4 nonsense mutations. The former was also associated with 
shorter survival. Collectively, these studies implicate a TGF-β ligand-independent gain of 
function role for mutant Smad4 in CRC. 
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CHAPTER 1: GENERAL INTRODUCTION 
OVERVIEW 
Colorectal Cancer (CRC) is the second most common cause of cancer death in 
the United States. Early-stage CRC is successfully treated by surgical intervention; 
however, relapse can occur even if the primary tumor was successfully removed during 
the initial treatment. Reemergence of colorectal cancer usually leads to metastasis, often 
resistant to the current chemotherapy regimen. Patients diagnosed with localized disease 
have about a 90% 5-year survival rate, compared to those diagnosed with metastatic 
CRC, which have only 14% 5-year survival rate1. Therefore, elucidating molecular events 
that lead to the advancement of CRC could open the door for future targeted therapies for 
such patients. 
About 10-30% of CRC patients harbor some loss of Smad4, a critical component 
of the TGF-β signaling pathway, either by deep deletion or missense mutations2. Based 
on limited research, naturally occurring Smad4 mutations are thought to be loss-of-
function. However, there is a big gap in our understanding of the role of mutant Smad4 in 
TGF-β signaling in CRC progression or any other acquired novel function, if any. Here, we 
provide relevant background information important to understand potential role of TGF-β 
signaling to CRC progression. 
COLORECTAL CANCER (CRC) 
In 2020, almost 148,000 individuals will be diagnosed with CRC and over 53,000 
will die from the disease. The majority of CRC cases occur in individuals 50 years of age 
or older, however, up to 12% of newly diagnosed CRC cases are attributed to individuals 
younger than 50 years1.  Although 10% of patients with CRC have a genetic predisposition 
to the disease, the majority of CRC cases are sporadic. 
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Benign GI tumors are a varied group but localized lesions that project above the 
surrounding tissue are commonly termed polyps. Although some polyps (termed 
hyperplastic polyps – polyps less than 5mm in size) are not a major precursor of CRC, the 
adenomatous polyp (adenoma) is thought to be the most important precursor lesion2. Even 
though only a fraction of adenomas will progress to cancer, there is a risk of CRC in 
individuals whose adenomas are not removed, and polypectomy decreases the risk of 
CRC 3,4.  
Figure 1. Molecular Events in CRC 
In the ‘classic’ CRC formation model originally developed by Dr. Bert Vogelstein 
(Figure 1), CRC pathogenesis occurs due to the progressive accumulation of genetic and 
epigenetic alterations. The loss of genomic stability accelerates the accumulation of 
mutations in oncogenes and tumor suppressor genes. This creates a  clonal growth 
advantage that leads to the outgrowth of malignant cells, which can ultimately develop into 
invasive adenocarcinoma5–7. Although some specific genetic events have been described 
as initiating events for CRC, the progressive accumulation of the alterations, rather than 
the order, seems to be key for the progression of colorectal tumors6.  
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At least two major genomic pathways are involved in the origin and progression of 
CRC: microsatellite instability (MSI) and chromosomal instability (CIN). About 15% of 
CRCs occur due to microsatellite instability (MSI), a genetic event that causes hyper 
mutability in the DNA as a result in loss of functional DNA mismatch repair genes (MMR)8. 
Most commonly, the promoter of hMLH1 will be hypermethylated, resulting in gene 
silencing9. In some instances, MSI can occur at protein-coding sequences that eventually 
result in point or frame-shift mutations that will yield a truncated, nonfunctional protein10. 
In these tumors, frequent inactivating mutations (~85% of colorectal tumors) occur to the 
transforming growth factor beta receptor 2 (TGFβRII)11 gene, a critical component of the 
transforming growth factor beta (TGF-β) signaling family.  
Chromosomal instability (CIN) represents 85% of sporadic CRCs12 and is 
characterized by allelic losses, amplifications, and translocations; usually associated with 
mutations in tumor suppressor genes or oncogenes13. This process involves the alteration 
of several pathways including the WNT pathway through the loss of APC, the addition of 
constitutive active mutations in KRAS or BRAF, mutations in the PI3K pathway, and 
inactivation of SMAD4 and TP53. Specifically: 
1. Adenomatous polyposis coli (APC) gene and WNT signaling pathway:  
Approximately 80% of all sporadic colorectal adenomas and carcinomas have 
somatic mutations that inactivate the tumor suppressor APC, a major binding 
partner and regulator of β-catenin in the canonical WNT signaling pathway3,14. 
Briefly, APC binds and collaborates with other proteins to form the β-catenin 
destruction complex, which ubiquitinates and targets β-catenin for proteasomal 
degradation15. APC inactivation will primarily result in the stabilization of β-catenin, 
which mimics constitutively active WNT signaling16.  
2. Mutations affecting the TGF-β pathway components in CRC: loss of 
heterozygosity (LOH) of chromosome 18q is observed more than 70% of CRCs17. 
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Two chromosome 18q tumor suppressor genes, SMAD2 and SMAD4,  encode 
proteins that function downstream of the TGF-β receptor complex18,19. Mutations 
that inactivate SMAD4 are found in ∼10–15% of CRCs, and SMAD2 inactivating 
mutations are found in ∼5% of CRCs. Mutations inactivating the SMAD3 gene, 
which maps to chromosome 15, are also only found in ∼5% of CRCs3,20–22.   
3. Alterations in the KRAS, BRAF, PIK3CA and PTEN signaling pathway: Ras 
family is comprised of a group of small GTP-binding proteins that regulate different 
signaling pathways involved in cell proliferation, differentiation, migration, survival 
and apoptosis23. Active Ras can bind to a variety of effector proteins, the best 
characterized being Ras kinases24 and phosphatidylinositol 3-kinases25 (PI3-K). 
It’s three members, KRAS, HRAS and NRAS are common targets for somatic 
mutations in human cancers23. KRAS somatic mutations are found in up to a half 
of CRC patients. The vast majority of mutations affect codon 12 and contribute to 
colorectal adenoma development17,26. Mutations of RAS are clinically relevant 
given that their presence interferes with the response of monoclonal antibodies 
against epidermal growth factor receptor (EGFR) like cetuximab and 
panitumumab27,28.  
 
Six research groups identified a consensus for gene expression based on a 
subtyping classification system for CRC, which resulted into four consensus molecular 
subtypes (CMS). The four CMS subtypes identified (CMS1- CMS4) differ in genetic and 
epigenetics, as well as the signaling pathways they follow. While CMS1 is characteristic 
of tumors with MSI, tumors with CIN can be subclassified based on gene expression: 
CMS2 (canonical subtype), CMS3 (metabolic subtype) and CMS4 (mesenchymal 
subtype)29.  
   
 
  5 
 
Around 14% of all CRCs are classified into the CMS1 subtype, from which the 
majority of patients (88%) have inherited disease and remaining 12% are sporadic (non-
inherited) CRCs29. They are also defined by having high BRAF V600E mutation rate30 and 
a widespread hypermethylation status, resulting in loss of tumor suppressor function. Out 
of the four subgroups, CMS1 tumors show marked upregulation of proteins involved in 
immune response pathways12,29.    
The CMS2 (canonical) subtype accounts for the largest number of CRC patients, 
with about 39%29. There are more frequent copy number losses in tumor suppressor 
genes and copy number gains in oncogenes in CMS2 compared to other subtypes. 
Thought to arise from the canonical adenoma-to-carcinoma pathway, the gene expression 
profile in CMS2 is often characterized by having hyperactive Myc and WNT/β-catenin 
signal transduction pathways29,31. CMS3 subtype, also known as the metabolic subtype, 
accounts for 37% of CRCs. Although KRAS mutations are present in every CRC subtype, 
they are significantly enriched in this subtype. CMS3 displays prominent metabolic 
activation, a hallmark that can prove useful for specific future targeted therapies31. Finally, 
CMS4 is defined by having microsatellite stable (MSS) CRC tumors. Tumors show 
upregulation of genes involved in EMT and it has signatures associated with the activation 
of TGF-β signaling. In addition, samples from CMS4 subtype have significant 
overexpression of proteins involved in angiogenesis, matrix remodeling pathways and the 
complement-mediated inflammatory system29,32. Overall, these specific subtypes can help 
determine treatment strategies for individual CRC patients, based on the mutation panel 
and activated pathways in their tumors. 
TGF-β and WNT pathways do not work in isolation, as there are examples of 
known interactions between them in cancer. β-catenin, the main effector of WNT signaling, 
has been found to form complexes with Smad proteins to enhance β-catenin protein 
stability and facilitate its transcriptional activity in chondrocytes33. The WNT effector LEF1 
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has been shown to co-occupy the CDH1 (E-cadherin) promoter with SMAD proteins, 
providing a molecular mechanism for the observed cooperation of WNT and TGF-β in 
EMT34.  For the next sections of this introduction, we focus on describing TGF-β and WNT 
signaling pathways and their deregulation in colorectal cancer, as it pertains to the 
understanding of this study.  
 
TRANSFORMING GROWTH FACTOR β (TGF-β) SUPERFAMILY SIGNALING 
OVERVIEW   
The transforming growth factor beta (TGF-β) is a family of secreted polypeptide 
growth factors which include TGF-βs, activins, nodals, bone morphogenic proteins (BMPs) 
and others that play an important role in a variety of cellular processes such as cell growth, 
differentiation, migration and apoptosis35.  
The TGF-β signaling pathway is activated by TGF-β ligands (TGFβ1, β2, and β3), 
which bring together receptor type I and type II (RI and RII), both serine/threonine kinase 
receptors. Upon receptor dimerization, type II receptors phosphorylate and activate type I 
receptors. Following receptor phosphorylation and activation, type I receptor kinase will 
directly phosphorylate the receptor-regulated Smads (R-Smads) on the last two serine of 
a conserved specific phosphorylation motif, SSXS, located at the extreme carboxyl 
terminus of the MH2 domain36. 
The TGF-β ligand will phosphorylate Smad2 and 3 while BMP ligand and receptors 
will activate Smad1, 5 and 8. Once activated, R-Smads will form a complex with Smad4, 
also known as common mediator Smad. Once the complex forms, it will translocate into 
the nucleus, bind to DNA and other transcription factors where it will modify a different set 
of target genes37,38.  
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TGFβRII receptors not only induce Smad-mediated responses but also activate 
Smad-independent responses, which allow additional versatility and diversification of 
TGF-β family responses. The non-Smad pathways include, but are not limited to, the 
activation of other mediators such as those involved in the Erk, JNK, and p38 MAPK 
kinase pathways39 (Figure 2).  
 
 
Figure 2. Smad-dependent and Smad-independent TGF-β signaling  
 
SMAD PROTEINS AS EFFECTORS OF TGF-β 
The eight-known Smads are around 500 amino acids in length and are divided into 
three classes according to their function. The receptor regulated Smads, or R-Smads, are 
direct substrates corresponding to their receptors. As mentioned above: Smad1, 5, and 8 
serve principally as substrates for BMP receptors, and Smad2 and 3 for the TGF-β 
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receptors. The common mediator Smad (co-Smad), Smad4, participates in TGF-β by 
binding to R-Smads. Lastly,  there are inhibitor Smads or I-Smads, which includes Smads 
6 and Smad7: they antagonize TGF-β signaling by interfering with Smad-receptor or 
Smad-Smad interactions35. Smad7 can inhibit both TGF-β and BMP, whereas Smad6 
preferentially inhibits BMP signaling40,41.   
 Smad proteins are composed of two globular domains, joined together by a 
proline-rich linker region. The Mad homology 1 (MH1) domain, located at the N-terminus, 
is highly conserved among all R-Smads and Smad4, but not Smad6 and 7. The MH1 
domain, which contains a β-hairpin structure, functions as a DNA-binding domain. The 
most abundant isoform of Smad2 contains a 30-amino acid insertion encoded in exon 3, 
which is thought to displace the β-hairpin loops, blocking its ability to bind to DNA42,43. A 
splice variant of Smad2 which lacks exon 3 (Smad2Δ3) binds to DNA equivalently to 
Smad344. Smad3 and Smad4 recognize a specific sequence in the DNA called the Smad-
binding element (SBE), which is defined as GCTC or its reverse complement, AGAC43.  
The MH1 domain is followed by a linker region, which contains several important 
peptide motifs including phosphorylation sites for several classes of protein kinases 
including MAPKs and CDKs35,45. R-Smads and I-Smads also contain a conserved proline-
tyrosine (PY) motif that mediates interaction with the WW domains in the Smad-interacting 
proteins Smurf1 and Smurf 2. Smurfs are E3 ubiquitin ligases of the C2-WW-HECT 
domain class that catalyze ubiquitin-mediated degradation of certain Smads and Smad-
associated proteins, including nuclear oncoprotein SnoN and the TGF-β-receptor 
complex46–48. The linker region in Smad4, however, contains a CRM1 recognized nuclear 
export signal (NES)49 and also part of the Smad activation domain (SAD)50, which is 
required for transcriptional activation.  
 The Smad MH2 domain is highly conserved among all Smads and is responsible 
for receptor recognition in the case of R-Smads, transactivation, interaction with 
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transcription factors and Smad-Smad oligomerization51–53 (Figure 3). A crystal structure 
for Smad4 revealed that Smad4 hetero-oligomerizes with Smad2 through a defined L3 
loop in the MH2 domain53 and several Smad-inactivating mutations found in tumors map 
to the MH2 domain interface and inhibit Smad oligomer formation54, including mutation 
hotspot region in CRC in Smad4 (Asp351-Pro356, Arg36) that is involved in binding to 
R-Smads55.  
 
Figure 3. Smad proteins and their structural elements  
 As stated above, activated Smad complexes accumulate in the nucleus, where 
they bind DNA directly or indirectly via other transcription factors and then regulate 
expression of different target genes. Smads interact with co-activators including p300 and 
CBP which have histone acetyl transferase (HAT) activity56. This interaction is mediated 
by the Smad activation domain in R-Smads and Smad4 (located within the linker and MH2 
domain) and is essential for maximal transcriptional activation57. Smads can also bind 
proteins that will repress Smad-dependent transcription, most famously Ski and SnoN 
proteins. Because the Ski binding surface on Smad4 overlaps with that required for 
binding of R-Smads, Ski and R-Smads compete for mutual exclusive binding to Smad4, 
leading to disruption of functional Smad4-R-Smad complexes58. Overall, binding of Smads 
to specific transcription factors allow for a variation in TGF-β functions.   
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COMMON MEDIATOR SMAD – SMAD4 
 As previously mentioned, Smad4 is referred to as the common mediator Smad due 
to it being a central mediator for both TGF-β and BMP signaling59. It is composed of 552 
amino acids (~60kDA) and its primary structure consists of three major parts, including 
the N-terminal MH1 domain, the C-terminal MH2 domain and the linker region in between 
them35. Smad4 forms a complex with Smad2 and Smad3, and translocate to the nucleus 
where it activates transcription of multiple TGF-β response genes35,36,49,53. Smad4 is an 
important component of the TGF-β signaling pathway and plays a critical role in its tumor 
suppressive role, mainly by inducing cell cycle arrest and apoptosis. For example, Smad4 
can induce p21CIP expression by binding to its promoter, resulting in inhibition of cell 
proliferation60,61.  
 
TGF-β SIGNAING IN CANCER  
 TGF-β signaling plays a dual role in cancer progression. In normal and 
premalignant cells, TGF-β acts as a tumor suppressor by inhibiting cell growth and 
inducing apoptosis. For example, Smad transcriptional complexes can target p15INK4b 
and p21CIP62,63 for transcriptional activation leading to cyclin-dependent kinase (CDK) 
inhibition and subsequent cell cycle arrest. Interestingly, the proto-oncogene c-Myc can 
block TGF-β induced growth arrest64. Smad3 can directly bind to a TGF-β inhibitory 
element (TIE) in the promoter of c-myc and repress its transcription65, leading to 
subsequent downregulation of c-Myc and upregulation of p21CIP66 and p15INK4b67.  
Even though TGF-β/Smad signaling can inhibit cell proliferation and induce 
apoptosis in non-cancerous cells, TGFβ1 mRNA is highly expressed within tumor tissues 
of many cancer types68. For example, CRC patients with high levels of TGF-β are 
associated with a high risk of cancer recurrence compared to those with low levels of TGF-
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β in their tumors69. This is because during the later stages of cancer, TGF-β acts as a 
tumor promoter by inducing tumor invasion and metastasis, which can be done through 
modulation of the surrounding tumor microenvironment. As an illustration, when CRC-
derived cell lines are engineered to secret active TGFβ1, they display increased 
metastasis in mice to both liver and lung. This event was found to be mainly driven by 
TGF-β activation in tumor-associated stromal cells69.  
An important effect of TGF-β on tumor progression is the induction of epithelial to 
mesenchymal transition (EMT), wherein epithelial-like tumor cells generate mesenchymal-
like characteristics, including decreased cell-cell adhesion and increased migration, 
invasion, and apoptosis-resistant properties70,71. TGF-β, among other tumor-associate 
growth factors, is responsible for the induction of multiple EMT-inducing factors including 
Snail, Slug, ZEB and Twist70. TGF-β regulates EMT through Smad-dependent and Smad-
independent pathways, such as PI3K/Akt, ERK1/2, p38 and MAPK. For example:  
1. Smad-dependent pathway EMT: Downregulation of Smad2 or SARA (Smad 
anchor for receptor activation; an endocytic adaptor protein that facilitates 
Smad2 binding to the TGFβRI and phosphorylation) increases the induction of 
EMT in human renal epithelial cells72. Also, ubiquitination of Smad4 by the E3 
ubiquitin ligase TIF1γ disrupted nuclear Smad complex, antagonizing TGF-β-
induced EMT in human mammary epithelial cells73.  
2. Smad-independent pathway EMT: On the other hand, TGF-β receptors can 
directly influence EMT via post-translational modifications of regulators of 
epithelial cell polarity and tight-junction assembly as is the case with Par6 
protein. TGFβRII will phosphorylate Par6, which in turn recruits Smurf1, an E3 
ubiquitin ligase. Smurf1 will then target RhoA for ubiquitination and 
degradation, resulting in loss of tight junctions and cell polarity74,75. Recent 
studies have also shown that TGF-β activates mTOR pathway during EMT via 
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PI3K and Akt76. The activation of mTOR, in turn, contributes to increased 
mRNA expression of transcription factor Snail which leads to changes in 
migration and invasion77.     
 
Among other processes that TGF-β can control is angiogenesis, the process by 
which new blood vessels form from pre-existing blood vessels. Tumors can co-opt this 
mechanism and use it to their advantage, allowing for increased nutrients and oxygen 
supply78. For many tumors, increased vascularity can result in metastasis as the new blood 
vessels provide a route by which tumors cells exit the primary tumor site and enter the 
circulation79. Vascular density can provide a prognostic indicator of metastatic potential, 
with the highly vascular primary tumors having higher incidence of metastasis than poorly 
vascularized tumors80. For example, our lab has shown that downregulation of Smad4 
protein in colorectal cancer cells results in increased angiogenesis in vivo, due to 
downregulation of antiangiogenic factor CTGF81. 
 
ALTERATIONS OF SMAD4 IN CANCER  
 Malignant cells can circumvent the suppressive effects of TGF-β either through 
inactivation of core components of the pathway, such as the receptors or by downstream 
alterations that disable the tumor suppressive arm the pathway37. Smad4 is an essential 
signal transducer of the transforming growth factor β (TGF-β) signaling pathway and is 
described as a tumor suppressor. Loss of Smad4 expression promotes malignancy in 
colorectal cancer tumors cells82 and serves as a prognostic marker in colorectal cancer 
patients83–85.  
Furthermore, Smad4 mutations are associated with the occurrence of JPS86 and 
mutations or deletions have been found in about half of pancreatic cancers as well as 
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approximately 10-30% of colorectal cancers2,87. In these tumors, Smad4 mutations appear 
more frequently in the MH2 domain and may be missense or nonsense mutations88. The 
reported nonsense mutation found in PDAC at amino acid 515 results in an unstable 
protein89 while missense mutations have been reported to affect the ability of Smad4 to 
form complexes with R-Smads in vitro90. Mutations found at the MH1 domain affect protein 
stability due to a higher susceptibility to ubiquitin-mediated degradation and they can also 
affect DNA binding or nuclear translocation91,92. Finally, there is a strong correlation 
between high frequency of Smad4 inactivation (either by deletions or point mutations) and 
distant metastasis in colorectal cancer93–95.  
 
WNT PATHWAY OVERVIEW AND DEREGULATION IN CRC  
 
The WNT pathway is commonly divided into β-catenin dependent (canonical) and 
independent (non-canonical) signaling. For this thesis, we will focus on describing and 
understanding the canonical WNT signaling pathway.  
 
 
Figure 4. Canonical Wnt/β-catenin dependent signaling pathway 
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The canonical WNT/β-catenin signaling pathway plays different cellular roles 
including regulating cellular proliferation, differentiation, tissue homeostasis and repair, 
and cellular apoptosis96. In the absence of WNT ligands (WNT-inactive state), β-catenin 
is phosphorylated by the destruction complex which leads to its subsequent ubiquitination 
and proteasomal degradation. The destruction complex contains scaffold protein Axin 
(which contains binding domains for β-catenin), tumor suppressor gene APC and the 
kinases GSK3β and casein kinase 1 (CK1)14. When in complex, β-catenin will be 
phosphorylated at Ser45 by CK1, followed by phosphorylation at Ser33, Ser37 and Thr41 
by GSK3β15,97,98. Phosphorylated β-catenin will be recognized and ubiquitinated by E3 
ligase β-TrCP 99–101 and targeted for degradation. Of note, the phosphorylation sites in β-
catenin are contained within the N-terminal domain, which is hotspot for mutations in 
cancers102–104.  
 In a WNT-active state, secreted WNT ligands will bind to Frizzled (Fzd) receptors 
and LRP5-6 co-receptors. LRP receptors will be phosphorylated by CK1 and GSK3β, 
which recruits Dishevelled (Dvl) proteins to the plasma membrane, where they polymerize 
and are activated14. This will ultimately result in the dissociation of the destruction complex, 
which allows β-catenin stabilization and translocation into the nucleus. There, β-catenin 
forms an active complex with lymphoid enhancer-binding factor 1 (LEF1) and T-cell factor 
(TCF) proteins and a host of co-activators to drive transcription of target genes105. 
Because it has no intrinsic ability to bind to DNA, β-catenin relies on DNA-binding factors 
to regulate gene expression106. Just like with the TGF-β signaling pathway, transcription 
of genes driven by WNT activation vary and depends on cell type96.  
 As mentioned in the beginning sections of this introduction, mutations in 
components of the canonical WNT signaling pathway occur in the majority of colorectal 
cancers with inactivating mutations in APC being most common. Mutations of APC were 
first identified in the germline of patients with familial adenomatous polyposis (FAP), a 
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hereditary condition that predisposes patients to intestinal polyps107. In colorectal cancer 
tumors, both alleles at the APC locus are affected by point mutations that can lead to stop 
codons or frameshifts leading to the deletion of the C-terminal half of the protein14. These 
mutations typically remove the interaction sites with Axin, leading to the inappropriate 
assembly of the β-catenin destruction complex16. β-catenin, however, is mutated in a small 
percentage of colorectal carcinomas (around 10%)14,108. The mutations affect specific 
serine and threonine residues which are essential for the targeted degradation of β-
catenin109.    
 
LEF1 TRANSCRIPTION FACTOR FAMILY  
 Because LEF1 is a key transcription factor downstream WNT signaling, we will 
detail the role of LEF1 protein in WNT signaling for the remainder of this section. LEF1 
belongs to the T cell factor (TCF)/LEF family of transcription factors, containing a highly 
conserved high mobility group (HMG) DNA-binding domain and plays a role of nuclear 
effects in the WNT/β-catenin pathway110. In the absence of nuclear β-catenin, LEF1 is 
bound to Groucho-related co-repressors, which recruit histone deacetylates (HDACs), 
resulting in the repression of WNT target genes111,112. Stabilization and translocation of β-
catenin into the nucleus displaces Groucho complexes when binding to TCF/LEF1113 and 
the active complex recruits histone-modifying coactivators such as CBP/p300114,115.  
TCF/LEFs functional roles are not just as activators, but some family members can 
also act as repressors. For example, while TCF1 and LEF1 are more linked to WNT target 
gene activation, TCF3 is generally known to be a WNT repressor106,110. On the other hand, 
TCF4 has been assigned either activating or repressor, depending on the isoform 
expressed. For instance, different TCF4 spliced isoforms have been studied in 
hepatocellular carcinoma cells. Those isoforms that contained an SxxSS motif were found 
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to be growth suppressive, whereas those lacking the element were WNT activating and 
growth promoting116,117.  
Altered LEF1 expression and function commonly occur in several cancers118. In 
many cases, increased LEF1 expression results in poor prognosis in some solid cancers 
including colorectal cancer119,120, oral squamous cell carcinoma121 and lung 
adenocarcinomas122. Given LEF1’s central role as a transcription factor in the WNT/β-
catenin signaling pathway, it makes for a potential target therapeutic cancer treatment. To 
illustrate, knockdown of LEF1 in colon cancer cells increased apoptosis in vitro and 
reduced tumor growth formation in vivo compared to control cells123. In glioblastoma cell 
lines, LEF1 knockdown inhibits invasion, migration, proliferation and self-renewal capacity 
of stem-like cells124.  
 
CURRENT COLORECTAL CANCER THERAPIES AND TREATMENTS  
CRC is a very heterogeneous disease and evidence over the years points to the 
fact that molecular and genetic features of a tumor can determine both the prognosis and 
the response to targeted treatment. Usually patients with colon cancers up to stage II can 
be treated by surgical resection only. Although the cancer might have grown through all 
the layers of the intestine and into nearby organs, colon cancer cells have not spread to 
neighboring lymph nodes. For stage II cancers, it is at the doctor’s discretion on whether 
or not to provide chemotherapy treatments to the patient125. Given the advances in primary 
and adjuvant treatments, the median overall survival time in CRC has seen much 
improvement. However, nearly 25% of patients with CRC present with metastases at the 
time of diagnosis and another 25% will subsequently develop metastasis26,126,127. 
Stage III colon cancers have spread to nearby lymph nodes, but they have not yet 
spread to other parts of the body. Adjuvant therapy is standard for stage III tumors, where 
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a combination of 5-fluorouracil plus oxaliplatin is used (where the mode of administration 
will depend on the protocol followed)128. Most people with stage IV cancer will get 
chemotherapies and/or targeted therapies to control the cancer. The goal of targeted 
therapy is to attack the cancer cells without damaging the surrounding ‘normal’ cells, thus 
leading to fewer side effects. Although each type of targeted therapy works a bit differently, 
they all interfere with the ability of the cancer cell to grow, divide, repair and/or 
communicate with other cells129. These therapies can include, but are not limited to, 
monoclonal antibodies against EGFR (cetuximab and panitumumab) and monoclonal 
antibodies against VEGF-A (bevacizumab)130, which targets angiogenesis.  
Despite the overwhelming evidence that both loss of TGF-β and hyperactivation of 
WNT pathway drive CRC, targeted therapies to the respective signaling pathways have 
yet to make it to the clinic. Several inhibitors/drugs that block TGF-β signaling might 
include small molecular inhibitors (SMI), neutralizing antibodies and others. Most current 
TGF-β signaling inhibitors aim to directly inhibit either TGF-β receptor kinase activity or 
TGF-β cytokine function131. Some drugs have received attention in the clinics. For 
example, LY33022859 is an anti-TGFβRII monoclonal antibody that inhibits receptor-
mediated TGF-β-signaling activation. Although tested in a subset of patients with 
advanced solid tumors, it was determined that dose escalation for this drug was unsafe 
due to negative symptoms132. Fresolimumab (GC1008), a human monoclonal antibody 
neutralizing TGF-β-1/2/3, was tested in phase 1 with patients with malignant melanoma, 
also resulting in many side effects and no significant clinical benefits133. Generally 
speaking, drugs targeting receptor kinase activity can lack absolute specificity and, at 
certain doses, also target activin and nodal signaling pathways131. 
Theoretically, WNT-targeting approaches can be divided into three categories: 1) 
targeting the WNT-ligand-receptor interface, 2) regulation of β-catenin destruction 
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complex and 3) direct interference with β-catenin mediated transcription134. Vantictumab 
(OMP-18R5) is an antibody targeting Frizzled receptors135 and Ipafricept is a Frizzled 
decoy receptor136. While both drugs have shown acceptable safety profiles for cancers 
such as breast, ovarian and pancreatic, neither is currently under investigation in CRCs. 
The reasoning behind, potentially, is that the majority of CRCs activate WNT signaling 
independent of WNT ligand. Because β-catenin is the central effector of the WNT signaling 
pathway, it seems the most reasonable approach to block WNT hyperactivation is by 
inhibiting its transcriptional response. However, complete ablation of β-catenin can be 
toxic to normal intestinal epithelium137. ICG-001 (PRI-724) is a small molecule that blocks 
interaction of β-catenin with its co-activator CBP138. Although initially developed as a 
potential treatment for multiple solid tumors, phase 1 trials for CRC indication are ongoing.  
Although targeted therapies have been great in providing a better quality of life for 
many CRC patients, it is also important to understand that they have certain limitations as 
they only work in tumor subtype specific manner and are limited by the tumors mutational 
profile. Understanding the functional role of CRC mutations is a pre-requisite for 
development of combination therapies.  
 
SUMMARY  
The general introduction provided above serves as a base to understand the body 
of work presented in this thesis. Although the consequence of loss of Smad4 (absence of 
the protein) has been heavily studied, there is a gap in the literature in understanding a 
molecular function (if any) for mutant Smad4 in colorectal cancer.  
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CHAPTER 2: MATERIALS AND METHODS 
 
Cell culture and treatments. Colorectal cancer cell lines SW480, SW620, and HCT116 
3:6 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% fetal bovine serum (FBS) and penicillin/streptomycin (p/s) at 37 °C and 5% CO2. For 
the TGF-β treatment experiments, recombinant human TGF-β (R&D systems, 240-B-010) 
was used at a concentration of 5 or 10ng/mL at the indicated time points. For the BMP2 
or BMP4 treatment experiments, recombinant human BMP2 (R&D systems, 355-BM-010) 
or BMP4 (R&D systems, 314-BP-010) was used at a concentration of 5 or 10ng/mL at the 
indicated time points. Cells were treated with recombinant Wnt3a ligand (R&D systems, 
5036-WN) at 100ng/mL at indicated time points.  
 
Transient transfections and retrovirus-mediated gene transfer. For infection of CRC 
cell lines with pMX-IRES constructs, retroviral particles were generated by transfection of 
HEK 293GP cells with Lipofectamine 3000 (Invitrogen). The virus-containing medium was 
collected after 8 hr or overnight and supplemented with 4 μg/ml polybrene (Sigma-Aldrich) 
and 1% FBS. Subsequently, the virus was filtered using 0.45 µm filter and viral 
supernatant was added to the target cells for 8 hours to overnight. Selection for infected 
cells was done with 12.5 μg/ml Blasticidin (Gemini Bio Products) for over a week.  
 
Plasmid generation. Plasmid encoding FLAG tagged, human Smad4 (Addgene item # 
14039) was first subcloned into pBlueScriptII vector and subsequently cloned into pMX-
IRES-Blasticidin (Gemini Bio Products) retroviral vector. R361 Smad4 point mutations 
were generated using Q5 Site-directed Mutagenesis kit (NEB Cat #E0554S) with primers 
that carry the desired mutation. For LEF1 constructs, FLAG/MYC tagged LEF1 was 
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purchased from Origene (CAT #RC208663). FLAG tag was substituted with an HA tag by 
using Q5 Site-directed Mutagenesis kit (NEB) according to manufacturer’s protocol.  
 
Chromatin Immunoprecipitation (ChiP) qPCR. SW480 cells (2.0 x 106) were fixed by 
1% formaldehyde for 10 min at room temperature and were then quenched by 125 mM 
glycine for 15 min at room temperature, washed with ice-cold PBS twice and centrifuged 
at 200g, 4°C for 5 min. The pellet was resuspended in 1 mL of cell lysis buffer (10 mM 
Tris-HCl, 10 mM NaCl, 0.5% NP-40, protease inhibitor) and kept at 4°C rotating for 30 min. 
After centrifugation, the pellet was resuspended in 1 mL of nuclear lysis buffer (1% SDS, 
10 mM EDTA, 50 mM Tris-HCl pH 8.0, protease inhibitor) and kept at 4°C for 60 min. 
Lysate was then sonicated to an average size of chromatin fragments of 0.25–1.00 kb and 
then frozen at -20ºC overnight. The chromatin was thawed on ice and centrifuged at 
2,500g for 30 mins. Immunoprecipitation and DNA purification experiments were 
performed using Chip-It High Sensitivity Kit (Active Motif # 53040) according to 
manufacturer’s protocol. The immunoprecipitated fraction was analyzed by qRT-PCR to 
determine the abundance of the target DNA sequence(s) relative to normal rabbit IgG 
control. 
Primer sequences (5’ to 3’) used: 
Table 1. Primers sequences used for ChIP qPCR  
Gene Locus Forward primer Reverse primer 
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Luciferase assay. SW480, HCT116 3:6 and SW620 cells (200,000 per well) were seeded 
into 12-well plates and rested overnight. Cells were then transiently transfected with 
SBE4-Luc (Addgene #16495), pGL3-BRE-Luc (Addgene #45126), TOP-FLASH (Addgene 
#12456) or FOP-FLASH (Addgene #12457) reporter plasmids for 24 hrs, using renilla 
luciferase as internal control. For TGF-β, BMP and WNT treatments, transfected cells 
were stimulated with TGF-β, BMP-2/4 or Wnt3a in serum-free media for an additional 24 
hrs. Firefly luciferase reporter activity was measured with a dual luciferase reporter assay 
kit (Promega), according to the manufacturer's protocol. Expression was calculated as the 
ratio of firefly luciferase units normalized to renilla luciferase. These experiments were 
independently repeated three times and each treatment consisted of triplicate samples. 
 
Western blotting and antibodies. Whole cell protein lysates were prepared in RIPA 
buffer (0.15M NaCl, l% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Triton X-
100, 1mM phenylmethylsulfonyl fluoride, 0.05M Tris-HCl, pH 7.4) containing protease and 
phosphatase inhibitors (Pierce Halt Inhibitor Cocktail, Thermo Scientific). Protein 
concentrations were estimated by Biorad colorimetric assay (BCA). Bound antibodies 
were detected with enhanced chemiluminescence (ECL kit, cat #) or by Odyssey Infrared 
Imager (LI-COR Biosciences). The following primary antibodies were used: Smad4, 
Smad2, Smad3, phospho-Smad2, phospho-Smad3, phospho-Smad1/5, BMPR2, Smad1, 
Actin, HA (Cell signaling) and FLAG (Sigma-Aldrich). For secondary antibodies, goat anti-
rabbit-HRP (GE Healthcare NA934V), goat anti-mouse HRP (GE Healthcare NA931V), 
goat anti-mouse-680 (Licor 925-32220) donkey anti-rabbit-800 (Licor 926-32213) were 
used. Dilutions were used according to the recommendation of the respective 
manufacturers.  
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CRISPR/Cas9 genome-editing system. Smad4 CRISPR/Cas9 knockout and homology 
directed repair plasmids were purchased from Santa Cruz Biotechnologies (sc-400110 
and sc-400110-HDR) and transfected into HCT116 3:6 cell lines through Lipofectamine 
3000 (per manufacturer’s protocol). Effective Smad4 knockdown was confirmed by 
western blotting.  
 
Isolation of nuclear and cytoplasmic extract. The nuclear extraction was prepared 
using an NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA) 
according to the manufacturer's instruction. Briefly, the treated cells were washed twice 
with cold PBS and centrifuged at 500 g for 3 min. The cell pellet was suspended in 100 μl 
of cytoplasmic extraction reagent I by vortexing. The suspension was incubated on ice for 
10 min followed by the addition of 5.5 μl of a second cytoplasmic extraction reagent II, 
vortexed for 5 s, incubated on ice for 1 min and centrifuged for 5 min at 16 000 g. The 
supernatant fraction (cytoplasmic extract) was transferred to a pre-chilled tube. The 
insoluble pellet fraction, which contains crude nuclei, was resuspended in 50 uL of nuclear 
extraction reagent by vortexing during 15 s and incubated on ice for 10 min, then 
centrifuged for 10 min at 16 000 g. The resulting supernatant, constituting the nuclear 
extract, was used for the subsequent experiments. 
 
Co-immunoprecipitation (co-IP). Cells stably expressing Flag-Smad4 (either wild-type 
or mutated) were collected and subsequently lysed in lysis buffer (50 mM Tris–HCl at 
pH 7.5 1M, 150 mM NaCl 5M, 1 mM EDTA, 1% Triton, 0.1% SDS, 0.5% NA-deoxycholate 
plus protease and phosphatase inhibitors) and incubated with anti-FLAG M2 Affinity Gel 
beads (Sigma-Aldrich) for 2 hrs at 4°C. The beads were washed 3 times with 
immunoprecipitation (IP) buffer (150 mM, NaCl, 50 mM Tris, pH 8, 1% NP-40, 0.25% 
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sodium deoxycholate) and bound proteins were eluted by boiling in nondenaturing sample 
loading buffer and loaded onto PAGE gels. For detecting binding of LEF1 and Smad4, 
expression constructs for LEF1-HA were transiently transfected into HCT116 3:6 cells 
(stably expressing Smad4) for 48 hrs. Cells were then collected, lysed and 
immunoprecipitation was performed as described above followed by detection through 
western blot.  
 
mRNA analysis. RNA was extracted using the RNeasy Kit (Qiagen) and TRIzol 
(Invitrogen) and cDNA synthesis was performed using the Maxima First-Strand cDNA 
Synthesis kit (ThermoFisher). Quantitative PCR analysis using SYBRGreen PCR Master 
Mix (Thermofisher) was performed according to standard procedures.  
Primer sequences (5’ to 3’) used: 
Table 2. Primers sequences used for qPCR  
Genes (all 
human) 
Forward primer Reverse primer 
PAI-1 ACAACCCCACAGGAACAGTC GATGAAGGCGTCTTTCCCCA 
SNAI2 CATGCCTGTCATACCACAAC GGTGTCAGATGGAGGAGGG 
PRSS8 CACCTTCTCCCGCTACATCC AGGAGGCTCACTGAGGGG 
NLRP2 GCAAAGGATGAAGTCAGAGAAGC TTTTGAAGCGCTCCAGCATT 
ACTIN AGCATCCCCCAAAGTTCAC  AAGGGACTTCCTGTAACAACG  
 
RNA-seq. Total RNA was extracted from SW480 cells using RNeasy Mini Kit (QIAGEN, 
#74104) and polyA+ transcripts were isolated with NEB Next Poly(A) mRNA Magnetic 
Isolation Module (NEB, #7490). RNA-Seq libraries were prepared with NEBNext Ultra II 
Directional RNA Library Prep Kit for Illumina (NEB, E7760S). Three biological replicates 
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were sequenced on a NextSeq 500 (Illumina) at a depth of at least 2x107 reads each. 
Reads were mapped and analyzed with a bioinformatic pipeline based on GSNAP, 
featureCounts, and the R packages limma and edgeR. We used human genome version 
GRCh38. GO analyses were performed using version 6.8 of the DAVID web server. GSEA 
analyses were performed using pre-ranked GSEA using a weighted scoring.  
 
Statistics and reproducibility. All statistical analyses were carried out using Graph Pad 
Prism (version 7) by unpaired student’s t-test for two group comparisons, Yate’s continuity 
corrected chi-square test for contingency table analysis, and Gehan-Breslow-Wilcoxon 
test for survival curves. Error bars represent s.e.m. ± SD and statistical significance were 
defined as P < 0.05. 
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CHAPTER 3: SMAD4 WITH R361 HOTSPOT MUTATIONS RETAINS THE 




In normal and premalignant cells, TGF-β can exert tumor-suppressive effects by 
inhibiting cell proliferation, stimulating differentiation and inducing apoptosis139. However, 
tumor cells can evade TGF-β tumor suppression through inactivation of either the 
receptors or downstream effectors, which disables the entire signaling cascade. For 
example, TGF-β RII is frequently mutated in colon carcinoma cells from patients with 
microsatellite unstable (MSI) CRC, a phenomenon defined by faulty DNA mismatched 
repair machinery5. Inactivating mutations in Smads, specifically Smad4, have been found 
in various types of cancers such as lung and pancreatic carcinomas83,87,140–142 and germ-
line mutations are common in juvenile polyposis, a disease which predisposes individuals 
to gastrointestinal malignancies86. Smad4 alterations are also found in 10-35% of CRC 
tumors and tend to appear late in the adenoma-to-carcinoma progression143,144. Complete 
loss of Smad4 in colorectal cancer patients can be due to deep deletions or frameshift 
mutations. We and other have shown that it is frequently associated with increased 
angiogenesis81,145, lymph node metastasis, advanced disease, and poor prognosis84. In 
addition, many patients acquire missense mutations, which cluster in the MH2 domain of 
the protein. While mutations in the MH2 domain mainly affect residues close to protein 
interface involved in hetero-oligomerization of Smad4 with R-Smads which is required for 
transcriptional activation53,55, mutations in the MH1 domain have been shown to alter 
protein stability and binding to the DNA49,146. Thus, Smad4 missense mutations are 
thought to be loss-of-function. However, there is a considerable gap in our understanding 
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of their role in CRC progression and whether these mutant forms of Smad4 retain or 
acquire any functions.  
In this results section, we report that R361 Smad4 variants can function 
independently from TGF-β-signaling and positively regulate WNT signaling, a pathway 
often hyperactivated in CRC16. We demonstrate that mutant Smad4 binds to lymphoid 
enhancer binding factor-1 (LEF1) protein and facilitates transcriptional activation of WNT 
signaling in CRC cells. Overall, we establish a novel function for mutant Smad4 proteins 
in the progression of colorectal cancer. 
 
RESULTS  
SMAD4 is frequently mutated in colorectal cancer  
To understand the clinical relevance of SMAD4 mutations in CRC, we analyzed 
SMAD4 mutation data in recent Memorial Sloan Kettering Cancer Center (MSKCC) study, 
which generated cancer gene panel data from 1,134 colorectal adenocarcinomas from 
patients with both metastatic and early-stage CRC. While all the TGF-β signaling 
components exhibit some genetic alteration, SMAD4 was the most frequently altered gene 
from the TGF-β signaling pathway (Figure 5A)21. Of all SMAD4 mutations and copy 
number alterations, missense mutations classified as putative drivers were the most 
abundant. Although they could be found across the MH2 domain, we confined subsequent 
analyses to amino acid substitutions in the R361 residue, as they were found at a much 
higher frequency than other missense mutations in this data set and other CRC 
studies143,147 (Figure 5B). 
To study R361 mutations in CRC cells, we generated retroviral constructs 
expressing either Smad4 wildtype (WT) or point mutations at the MH2 domain of Smad4, 
specifically at the arginine 361 residue (R361) and bearing FLAG tag at the N-terminus. 
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We transduced those constructs into cells lines that lack detectable endogenous Smad4 
protein, SW480 and SW62088, but have otherwise intact TGF-β signaling pathway 
components148 (Figure 6A). After transduction with the retroviral constructs, we were able 
to detect robust protein expression by Western blotting using the α-Smad4 antibody 
(Figure 6B). To study the Smad4 mutations in additional TGFβ-responsive cell lines, we 
used an HCT116 engineered derivative HCT116 3:6, which have intact TGF-β 
signaling149. To render them Smad4-deficient, we used Santa Cruz CRISPR-Cas9 
knockout (KO) and homology directed repair (HDR) plasmid according to manufacturer’s 
protocol. Edited HCT116 3:6 cells were cloned using flow cytometry and a single cell clone 
with no trace of Smad4 expression was identified using Western blotting (Figure 6C & 6D). 
When comparing the level of expression between parental HCT116 3:6 cells (which 
express endogenous Smad4 protein) and our retroviral constructs, we observe that 
HCT116 3:6 cell lines transduced with Smad4-retroviral constructs express ~2-3X as 
much Smad4 protein as those with endogenous Smad4 (Figure 6E). Thus, although levels 
of retrovirally expressed Smad4 didn’t exactly match those seen in CRC, they were not 
grossly elevated either. Finally, the effects of R361-mutation on the turnover of Smad4 
was examined in SW480 cells using cycloheximide treatment (25ug/mL for 0, 6 and 12 
hrs). It was observed that both Smad4-WT and Smad4-R361H/C protein start degrading 
between 6-12 hrs (Figure 6F), suggesting that mutations at the R361 residue did not affect 
the half-life of Smad4 protein. 
  
   
 




Figure 5. Smad4 is frequently mutated in CRC. (A) MH2 hotspot mutations of SMAD4 
are marked on the lollipop plot downloaded from the MSKCC (2018) study on cBioportal. 




   
 




Figure 6. Generation of Smad4 CRC mutant cell lines. (A) Western blot analysis of 
cells lacking endogenous expression of Smad4, using HCT116 3:6 as positive control. (B) 
Western blotting confirming retroviral expression of Smad4 in SW480 and SW620 cell 
lines. (C) Western blot comparing levels of Smad4 protein in A549, HEK293, HCT116 3:6 
and HCT116 3:6 Smad4 KO cell lines. Actin was used as loading control. (D) Western 
blotting confirming retroviral expression of Smad4 in HCT116 3:6 cells. (E) Western blot 
comparing the levels of endogenous versus retroviral transduced Smad4 protein. Actin 
was used as a loading control. (F) Determination of Smad4 half-life. SW480 cells were 
treated with 25ug/mL of cycloheximide for either 0, 6 or 12 hrs, followed by western blot 
with the indicated antibodies. p21 was used as a positive control and actin was used as a 
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SMAD4 R361 missense mutations prevalent in colorectal cancer result in loss of 
binding to phosphor-Smad2/3  
Because Smad4 is an important factor in TGF-β signaling, we asked whether there 
were major differences in TGF-β upstream signaling pathway. Stimulation of these two 
cell lines for 1 hour with 5ng/mL of TGF-β resulted in phosphorylation of receptor regulated 
Smads (i.e., Smad2 and Smad3, Figure 7A) regardless of Smad4 status. This was 
expected since phosphorylation of Smad2/3 is an initial step in the TGF-β signaling 
cascade and upstream of Smad4 signaling. However, R361 is in the loop helix region of 
the Smad4 MH2 domain and is an important residue in forming a Smad4 heterocomplex 
with R-Smad38. To test whether mutations at the R361 residue are still able to bind to 
phosphorylated Smad2 and Smad3, we performed immunoprecipitation analysis on 
SW480 cells treated with either vehicle control or soluble TGF-β. While wild-type Smad4 
was able to bind to both R-Smads, both mutations R361H and R361C abolished 
interaction with R-Smads in CRC cells (Figure 7B). This suggests that this missense 
mutation affects heterodimerization between Smad4 and Smad2/3 but does not affect 
overall phosphorylation of Smad2/3. 
In a basal state, Smad4 is distributed throughout the cell and may undergo 
continuous shuttling between the cytoplasm and nucleus – presumably due to the 
combination of an active nuclear localization signal (NLS) in its MH1 domain and its 
nuclear export signal (NES) in its linker region. During active TGF-β signaling, binding of 
R-Smads to Smad4 is thought to mask the NES in Smad4, thus allowing the complex to 
accumulate in the nucleus49. Because R361 mutations are unable to associate with R-
Smads, we decided to investigate whether or not Smad4 mutations can concentrate into 
the nucleus following TGF-β treatment. Following treatment with soluble TGF-β ligand, 
only wild-type Smad4 was able to accumulate in the nucleus while Smad4-R361H and 
Smad4-R361C mutants could not. (Fig. 7C, 7D quantification). These results suggest that 
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Smad4-R361 mutations are unable to bind to R-Smads and cannot concentrate in the 
nucleus in the presence of active TGF-β signaling.  
  
   
 




Figure 7. Smad4-R361 mutations cannot bind p-Smad2/3 in CRC cells in response 
to TGFβ. (A) SW480 and SW620 cell lines treated with either vehicle control or 5ng/mL 
for an hour. Western blotting was performed to detect phosphorylation of Smad2 and 
Smad3, and total levels of Smad2 and Smad3 as indicated. Actin was used as loading 
control. (B) SW480 cells were treated at 0' or 60' with soluble TGF-β followed by 
immunoprecipitation with FLAG conjugated beads. Input/Whole Cell Lysate (WCL) was 
used as a control. (C) SW480 cells were treated at 0' or 60' with soluble TGFβ followed 
by a nuclear cytoplasmic fractionation. Lamin A/C was used as nuclear marker and alpha 
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Smad4 mutants do not support canonical TGF-β-induced transcriptional activity 
Activated Smad complexes accumulate in the nucleus, where they can bind 
directly or indirectly to DNA and regulate gene expression. Because Smad4 is a critical 
effector of TGF-β signaling, we tested whether R361 mutations in Smad4 have altered 
transcriptional activity. Smad4 wild-type and Smad4 mutant stably expressing cells lines 
were transiently transfected with a luciferase vector containing 4 copies of the Smad 
binding element (SBE), a sequence that allows for Smad-DNA binding43. As expected, 
Smad4-WT was able to support downstream TGF-β transcriptional activity in the presence 
of soluble TGF-β in all three of our CRC cells lines (SW480, SW620 and HCT116 3:6). 
However, both Smad4-R361 mutations were unable to support canonical TGF-β 
transcriptional activity and behaved similarly to the empty-vector cells (Figure 8A). There 
has been uncertainty as to whether mutations in Smad4 could exert a dominant-negative 
effect over Smad4-WT62,89. We therefore tested the ability of mutant Smad4 to interfere 
with Smad4- mediated TGF-β responsive transcription. Due to ease of transfection, we 
used the HCT116 3:6 Smad4 knockout (KO) clone cell line to test whether or not mutant 
Smad4 acted in a dominant negative manner over wild-type Smad4. Transfection of 
increasing amounts of either Smad4-R361H or -R361C had no effect on induction of SBE 
reporter gene by TGF-β (Figure 8B) arguing against the dominant negative mechanism. 
To further confirm the decrease in transcriptional activity of Smad4-R361 mutants, we 
performed quantitative analysis of Smad4-targeted gene expression by real-time 
quantitative RT-PCR (qRT-PCR). The expression of PAI-1 and SNAI2, both well-validated 
direct Smad4 target genes, was compared in SW480 cells expressing different Smad4 
constructs and the empty vector. Consistent with the reporter assay, in TGF-β-treated 
SW480 cells, only Smad4-WT was able to induce the expression of these Smad4 target 
genes by more than 2-fold, whereas this induction was not seen in cells overexpressing 
Smad4- R361 mutations (Figure 8C).  
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Smad4 binds directly to the promoter region of PAI-1150. To provide further 
evidence that mutant Smad4 is unable to regulate PAI-1 gene expression in the presence 
of TGF-β, we performed chromatin immunoprecipitation (ChIP) assay followed by qRT-
PCR. As expected, stimulation of cells with TGF-β induced the recruitment of Smad4-WT, 
but not Smad4-R361 mutant protein to the promoter region of PAI-1 (Figure 8D). Taken 
together, these data indicated that Smad4-R361 mutations completely disengage from the 
TGF-β pathway and neither activate nor repress canonical TGF-β signaling, even when 
overexpressed. 
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Figure 8. Stably expressed Smad4 mutants do not support canonical TGFβ-induced 
transcriptional activity. (A) SW480, SW620 and HCT116 3:6 cells transfected with the 
SBE-Luciferase construct, later treated with either vehicle control or soluble TGFβ ligand. 
pRL-TK plasmid was used as an internal control. (B) HCT116 3:6 cells were transiently 
transfected SBE-Luciferase construct, with either a 1:1 or a 1:3 ratio of Smad4-
WT:Smad4-R361 mutant plasmid for 24 hours, followed by treatment with either vehicle 
control or soluble TGFβ for another 24 hours. Cells were then lysed, and luciferase activity 
in lysates was determined. Renilla plasmid was used as an internal control. (C) Induction 
of PAI-1 and SNAI2, TGFβ target genes, were measured after TGFβ treatment by qRT-
PCR in SW480 cells. Actin was used as internal control. (D) SW480 cells were plated and 
treated with 10ng/mL of soluble TGFβ for an hour. Chromatin fraction was prepared from 
harvested cells to analyze binding of Smad4 to indicated promoter using ChIP-qPCR with 
anti-Smad4 or anti-IgG.  
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Smad4 mutants do not support canonical BMP-induced transcriptional activity 
Although our studies so far have mainly focused on the TGF-β signaling pathway, 
it is important to reiterate that Smad4 can mediate gene responses in a variety of other 
pathways. One of the other well studied TGF-β signaling pathways is that of Bone 
Morphogenic Protein (BMP). BMP ligands also bind to type II and type I serine-threonine 
kinase receptors and mediate their signaling through both Smad and non-Smad signaling 
pathways. As mentioned in Chapter 1 of this thesis:  of the eight Smad proteins identified 
in mammals Smad1, Smad5 and Smad8 are the R-Smads activated by BMP type I 
receptors151.  While BMPs can be divided into several subgroups, BMP-2/4 group has 
been most recently identified to play a role in colorectal cancer152.  
 Due to the fact Smad4 (co-Smad) is shared by both BMP and TGF-β signaling 
pathways, we also wanted to understand whether or not mutations in Smad4 affects BMP 
signaling. Because phosphorylation of R-Smads is the initial step in activation, we decided 
to look at the effect of BMP upstream signaling pathway. Stimulation of SW480 for 1 hour 
with 50ng/mL of either BMP2 or BMP4 resulted in phosphorylation of receptor regulated 
Smad1/5 in cell lines expressing wild-type Smad4. Interestingly, we see that cells 
containing no Smad4 or Smad4-R361 mutation have reduced phosphorylation of R-
Smads (Fig 9A), an event that we did not see when we treated cells with TGF-β and 
analyzed phosphorylation of Smad2/3 (Fig 7A). This event, however, would need to be 
confirmed in the other CRC cell lines used in our study.  
Similarly, in our SBE-luciferase assays, Smad4-WT was able to support 
downstream BMP transcriptional activity in the presence of soluble BMP2 and BMP4 in 
SW480 and HCT116 3:6 cell lines. However, both Smad4-R361 mutations were unable to 
support canonical BMP transcriptional activity and behaved similarly to the empty-vector 
cells (Fig 9B). Finally, to test whether Smad4-R361H is still able to p-Smad1/5, we 
performed immunoprecipitation analysis on SW480 cells treated with either vehicle control 
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or soluble BMP2 and BMP4. Similar to our p-Smad2/3 assay, only wild-type Smad4 was 
able to bind to p-Smad1/5 as Smad4-R361H completely abolished that interaction (Fig 
9C). Overall, mutating R361 residue affects heterodimerization of Smad1/5 and 
downstream BMP signaling.  
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Figure 9. Smad4-361 mutations result in loss of downstream BMP signaling (A) 
SW480 cell lines treated with either vehicle control or 50ng/mL of BMP2 or BMP4 ligand 
for an hour. Western blotting was performed to detect phosphorylation of Smad1/5, and 
total levels of Smad1 and BMPR2 as indicated. Actin was used as loading control. (B) 
SW480 and HCT116 3:6 cells transfected with the BRE-Luciferase construct, later treated 
with either vehicle control or 50ng/mL of BMP2 or BMP4 ligand. pRL-TK plasmid was used 
as an internal control. (C) SW480 empty, Smad4-WT and R361H expressing cells were 
treated with either vehicle, BMP2 or BMP4 ligand followed by immunoprecipitation with 
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R361H confers the gene signature associated with LEF1 protein overexpression. 
 Although with respect to canonical TGF-β targets Smad4-R361 mutations appear 
to be loss-of-function, we reasoned that a hotspot mutation is more consistent with a gain-
of-function mechanism. To uncover such a mechanism, we performed RNA-Seq analysis 
on SMAD4-transduced SW480 cells treated with soluble TGF-β for 24 hr (Figure 10A). 
Principal component analysis (PCA) performed on all expression datasets revealed that 
as expected, Smad4-WT is the only group strongly affected by the treatment with soluble 
TGF-β (Figure 10B). However, unexpectedly, the SMAD4 mutant samples separated very 
strongly from the SMAD4-null samples, with or without TGF-β treatment. This separation 
was the first experimental evidence of nonequivalence of SMAD4-null and missense 
mutations. To understand the specific differences between CRC cells expressing no 
Smad4 and Smad4-R361 mutations, we further analyzed our RNA-Seq data set by gene 
set enrichment analysis (GSEA). We discovered that Smad4 R361H-associated genes 
are most significantly enriched in the members of the following datasets: genes down or 
up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 (Figure 10C). This 
enrichment was strongly driven by the cluster of genes that were expressed at high levels 
in SMAD4-null cell but downregulated in SMAD4-WT and especially in SMAD4-MUT cells 
(Figure 10D) such as known colon cancer metastasis suppressor PRSS8153, putative CRC 
tumor suppressor RAB25154, and an NF-kB inhibitor NLRP2155. To confirm that a 
transcriptome associated with LEF1-levels was indeed affected, we reproduced RNA-seq 
results by analyzing single genes by qRT-PCR. Indeed, we saw that transcription of genes 
included in the list: NLRP2 and PRSS8 showed downregulation in cells containing both 
Smad4 R361H and R361C mutant compared to cells expressing no Smad4. Of note, 
RAB25 was significantly downregulated in cells expressing Smad4-R361C, but not 
Smad4-R61H, when compared to empty vector cells (Figure 10E). 
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 The RNA-seq data showed that LEF1-associated gene signature is affected in 
cells expressing Smad4 mutant vs empty vector cells. To study this effect at the molecular 
level, we first determined that the level of LEF1 protein was unchanged between empty 
vector, Smad4-WT and Smad4-R361 CRC cells (Figure 11A). Previous studies have 
demonstrated that Smad4 WT and LEF1 can bind each other in neuroblastoma and 
fibroblast-like cells156,157. To investigate whether or not Smad4-R361 mutants can bind 
LEF1 protein in CRC cells, we transiently transfected Smad4-transduced HCT116 3:6 
cultures with an HA-tagged LEF1 construct followed by immunoprecipitation. We observed 
that both Smad4-WT and Smad4 R361H/C can bind LEF1 protein in CRC cells (Figure 
11B), but the consequences of this interaction remained to be determined.  
It’s been previously shown amino acids 511-552 are crucial for interaction of 
SMAD4 with LEF1157. However, when we tried to generate a Smad4Δ510-552 construct, 
we are unable achieve Smad4 protein expression as examined through western blot 
analysis (data not shown). To determine the domain essential for Smad4-LEF1 interaction, 
we generated two Smad4 deletion constructs: Smad4Δ535-552 and Smad4Δ543-535 
(Figure 11C). We first transfected these constructs into HEK cells to validate their 
expression (Figure 11D) via western blot, and then tested whether or not they could retain 
binding to LEF1. Again, we transiently transfected Smad4-transduced HCT116 3:6 
cultures with an HA-tagged LEF1 construct followed by immunoprecipitation. We observed 
that while Smad4-WT can bind to LEF1 protein, that binding is significantly reduced in 
both Smad4Δ535-552 and Smad4Δ543-535 samples (Figure 11E and 11F, 
quantification). This led us to believe that Smad4 amino acids 535-552 might be essential 
for binding to LEF1.  
As LEF1 is a key downstream effector of the WNT pathway, we evaluated WNT 
signaling status in our CRC cell lines. Specifically, we employed the TOP-Flash/FOP-
Flash luciferase reporter that contains 7 copies of TCF/LEF binding sites. When incubated 
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in basal media, R361 Smad4 mutants were able to induce downstream WNT signaling at 
higher levels compared to no-Smad4 and wild-type Smad4 in both SW480 and HCT116 
3:6 cells (Figure 12A). Since SW480 are not responsive to Wnt3a (data not shown), we 
continued our studies with HCT116 3:6 cells. When HCT116 3:6 Smad4 cells were treated 
with soluble Wnt3a ligand, we observe an increase in WNT signaling compared to vehicle 
control. In addition, there was significant up-regulation of WNT signaling by R361 mutants 
when compared to cells expressing no Smad4 and wild-type Smad4 (Figure 12B). We 
conclude that these two Smad4 mutations, which are associated with the loss of TGF-β 
response in human cancer cells, still retain a TGF-β-independent function of Smad4, 
activation of downstream WNT signaling. 
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Figure 10. R361H has the gene signature associated with upregulation of TCF/LEF1 
protein complex. (A) Schematic representation of our RNA-Seq workflow. (B) Principal 
component analysis (PCA) for different treatment groups as indicated. (C) GSEA summary 
of pathways associated with genes differentially regulated in cells expressing Smad4-
R361H vs empty vector expressing cells. (D) Heat map representing the gene expression 
in CRC cells expressing Smad4-R361H mutant, Smad4- WT and empty vector (E) qRT-
PCR validation on NLRP2, PRSS8 and RAB25 transcript on SW480 cells. Actin was used 
as endogenous control and empty vector cells were used to normalize expression of all 
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Figure 11. Smad4-binds to LEF1. (A) Western blotting showing the levels of Lef1 protein 
in SW480 cell lines. (B) HCT116 3:6 cells were transfected with Lef1-HA constructs for 48 
hours followed by immunoprecipitation with FLAG-conjugated beads. Input/Whole Cell 
Lysate (WCL) was used as a control. Asterisks represent unspecific band in the empty 
vector lane, likely due to antibody background. Immunoprecipitation was repeated three 
times with the same results. (C) Diagram of Smad4 mutation constructs generated to test 
which domains are necessary to bind to LEF1. (D) HEK cells were transiently transfected 
with Smad4-WT, ∆Smad4 535-552 and ∆Smad4 543-552 to confirm expression of protein. 
Actin was used as loading control. (E) IP and western blot assays showing the interaction 
between Smad4 and LEF1 in HCT116 3:5 cells transfected with different FLAG-tagged 
Smad4 deletion constructs and HA-tagged LEF1 construct. Asterisks represent unspecific 
band in the empty vector lane, likely due to antibody background. (F) Quantification of 
blots from panel E.  
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WNT activation and SMAD4 missense mutations in primary CRCs  
We then asked whether there is an epistatic relationship between Smad4 
missense mutations and WNT activation in CRC patients. To answer this question, we re-
analyzed the MSKCC cancer panel study. In microsatellite stable CRC samples, SMAD4 
has a 15% frequency of mutation while CTNNB1 (β-catenin) has a lower mutation 
frequency of 4% (Figure 12C), likely due to APC already being mutated in many CRC 
patients14. We reasoned that if SMAD4 missense mutations aid WNT signaling, activating 
missense mutation in CTNNB1 will be under even less selective pressure to occur. This 
would be in contrast to SMAD4 truncating mutations, which do not affect WNT signaling. 
To compare and contrast the co-occurrence frequency of CTNNB1 mutations in CRCs 
alongside either SMAD4 missense or loss-of-function nonsense mutations89,158, we 
utilized the chi-square test with Yate’s correction. Indeed, we observed highly statistically 
significant enrichment for CTNNB1 mutations in CRC with nonsense mutations, at the 
expense of tumors with SMAD4 missense mutations (Figure 12D). 
Finally, to understand the contribution of R361-mutations to clinical outcomes in 
CRC patients, we analyzed median overall survival (OS) in the MSKCC cohort. When 
compared with patients with no SMAD4 alterations, patients with SMAD4 missense 
mutations had a shorter OS survival of 70.03 vs 40.5 months (p = 0.0186). This difference 
was not be observed in patients that had no alteration for SMAD4 versus patients with 
SMAD4 truncating nonsense mutations (OS survival of 70.03 vs 68.3 months respectively, 
p = 0.9076) (Figure 12E, left and right). These data demonstrate that CRC patients with 
SMAD4 missense mutations do worse overall than those with unaltered SMAD4 and 
truncating mutations in SMAD4, attesting to their gain-of-function properties. 
  
   
 






Figure 12. Smad4 R361 mutants boost Wnt signaling. (A) SW480 and HCT116 3:6 
cells were transfected with either a TOP-flash or FOP-flash construct and collected after 
48hrs. pRL-TK plasmid was used as an internal control. (B) HCT116 3:6 cells were 
transfected with either a TOP-flash or FOP-flash construct, later treated with either vehicle 
control or Wnt3a ligand. pRL-TK plasmid was used as an internal control. (C) Oncoprint 
of SMAD4 and CTNNB1 mutations of MSS CRC patient samples, which were then 
analyzed using the cBio Portal for Cancer Genomics platform. (D) CRC patients with 
SMAD4 missense mutations containing CTNNB1 missense mutations (3) or CTNNB1 
wild-type (123) or SMAD4 truncating mutations containing CTNNB1 missense mutations 
(6) or CTNNB1 wild-type (48). Statistical significance using Yate’s continuity corrected chi-
square test: p = 0.00367. (E) Comparison of survival curves in patients with no SMAD4 
alterations and SMAD4 missense mutations (left) and no SMAD4 alterations and SMAD4 
truncating mutations (right). Statistical significance per log-rank (Mantel-Cox) test: p = 
0.0186 and p = 0.9076 respectively. 
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DISCUSSION 
Defects in Smad4 play a significant role in the malignant progression of tumors 
and are frequently altered in colon and pancreatic carcinomas21,83. About 10-30% of CRC 
patients harbor some loss of Smad4, either by deep deletion or nonsense mutations. 
Interestingly, missense mutations in Smad4 also have been identified in variety of cancers 
including CRC. In these tumors, Smad4 mutations appear frequently at the MH2 domain. 
By analyzing both primary tumors and immortalized cells lines, two of the most frequent 
Smad4 missense mutations have been identified at position 361 which results in a 
substitution from arginine to either histidine or cysteine55. These genetic hits are 
recurrently detected in Smad4, consistent with the idea that this gene acts as a tumor 
suppressor. On the other hand, their clustering in distinct hot spots argues that Smad4 
mutants, similar to mutant have an oncogenic function; however, this hypothesis has not 
been previously tested. 
In the present study, we investigated the functional roles of the missense mutations 
R361H and R361C in the Smad4 MH2 domain that naturally occur in human colorectal 
cancer patients55. This was achieved by the means of retroviral transduction into cell lines 
that lack endogenous Smad4 protein. Smad4 missense mutations had been previously 
mapped onto the crystal structures of Smad heterodimers, specifically onto the defined 
protein loop that is directly involved in binding to the R-Smads. Our co-
immunoprecipitation experiments indicate that point mutations in Smad4 MH2 domain 
indeed disrupt binding to endogenous p-Smad2, p-Smad3 and p-Smad1/5. We also 
showed in transfection assays that Smad4 missense mutations cannot support 
transcription from reporters driven by Smad3–Smad4 (CAGA12- luciferase) complexes. 
In addition, Smad4-R361 mutations could also not support downstream BMP signaling 
when we used a BMP-specific reporter. Although it seems that these mutations also 
cannot activate downstream BMP signaling, more experiments would be needed to solidify 
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this claim. For example, apart from looking at BMP-signaling using a reporter assay, we 
could confirm loss of canonical BMP target genes such as Id1 and Id2153,154 via qRT-PCR. 
In addition, we could also determine if Smad4 can bind to the promoter of BMP target 
genes through Chromatin Immunoprecipitation (ChiP) as we did with TGF-β/SMAD4 
target, PAI-1. 
Admittedly, some tumor suppressor genes can have dominant negative effects. 
For example, mutant p53 protein can bind to its wild type counterpart encoded by the 
unaltered allele and sequester it in non-functional complexes159. However, when we co-
expressed mutant and wild- type Smad4, we observed no dominant negative effects of 
the former. Taken at face value, these experiments would suggest that Smad4 variants 
are loss-of-function. This mechanism is supported by several lines of genetic evidence, 
including a frequent loss of heterozygosity (LOH) at chromosome locus 18q where SMAD4 
is located; such loss is associated with a poor prognosis for CRC patients160,161. Yet the 
very high prevalence of R361 SMAD4 mutations in CRC patients, particularly in those with 
distant metastasis vs. locally advanced tumor93  indicated that additional molecular 
mechanisms could be at play. 
The idea that Smad4 can lose canonical TGF-β functionally but maintains some 
TGF-β-independent function had been proposed before. For example, it was suggested 
previously that Smad4 cooperated with LEF1 to increase c-myc expression in the absence 
of TGF-β signaling162; however, that study did not investigate the effect of this interaction 
on WNT signaling. Furthermore, to our knowledge, the ability of mutant Smad4 to bind to 
LEF1 and the consequence of that binding has not been previously studied. Here, we 
propose that Smad4-R361-mutant loses its tumor suppressive arm and retains binding to 
LEF1, resulting in enhanced WNT signaling. We do not know for the fact why there is more 
WNT signaling in Smad4-R361 CRC expressing cells compared to those expressing 
Smad4-WT. It is possible that the inability of Smad4 R361 mutant to bind R-Smads 
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following TGF-β stimulation increases the pool of available protein to bind to LEF1; 
however, more experimentation will be required to test this hypothesis. In addition, it is 
possible that this LEF1-Smad-R361complex does not act alone, and could include other 
transcription factors, such as β-catenin, to assist in downstream activation of WNT 
signaling. However, β-catenin binding has been understudied and independent 
publications yielded mixed results163–165.  
The four CMS subtypes differ in genetic and epigenetics, as well as the signaling 
pathways they follow. While CMS1 is characteristic of tumors with MSI, tumors with CIN 
can be subclassified on the basis of gene expression: CMS2 (canonical subtype), CMS3 
(metabolic subtype) and CMS4 (mesenchymal subtype)31. Copy number variation in both 
oncogenes and tumor suppressor genes are found more frequently in CMS2 than in other 
subtypes and they display a strong upregulation of WNT and MYC downstream targets. 
Interestingly, SMAD4 mutations were profiled across different molecular subtypes and 
found to be most common with the CMS3 subtype143, however, that classification was not 
specific to SMAD4 missense mutations. Based on our data and overall working model, we 
would expect that SMAD4 missense mutation (especially hotspot mutation R361) to be 
commonly found in the CMS2 subtype due to their marked upregulation of WNT pathway. 
However, this hypothesis could not be tested directly using our dataset due to the lack of 
RNA-Seq data in the MSKCC cohort.  Nevertheless, based on our survival data, the 
interaction between Smad4-R361 and LEF/TCF protein complexes may be a good 
therapeutic target.  
Our work raises additional questions that will be addressed in future studies. TGF-
β not only induces Smad-mediated responses, but also activate Smad-independent 
responses, which allow additional versatility and diversification of TGF-β family responses. 
The non-Smad pathways include, but are not limited to, the activation of other mediators 
such as those involved in MAPK kinase pathways39. Loss of Smad4 has been shown to 
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induce tumorigenicity and 5-FU (5-fluoracil) resistance through activation of the Akt 
pathway, which results in upregulation of anti-apoptotic proteins166. Another study 
revealed that patients with advanced disease observed a markedly shorter progression-
free survival time in patients with SMAD4-mutated tumors than in those wild-type for 
SMAD4, when treated with anti- epidermal growth factor receptor (EGFR) treatment143. 
This suggests that mutant Smad4 might be playing a role that affects signaling pathway, 
possibly via binding to other, yet to be identified transcription factors. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS  
OVERVIEW  
As we summarize our findings and conclude our discussion, we end with an 
examination on future directions of this thesis project. We provide proposals for future 
experiments that will validate our findings, make suggestions of various avenues to pursue 
that could provide valuable insight, and outline how breakthroughs on defining this 
pathway further can open up possibilities to create better therapies for CRC cancer 
patients. 
 
LIMITATIONS OF COMPLETED WORK & FUTURE DIRECTIONS  
Elucidating molecular mechanism by which Smad4 R361 regulates WNT 
signaling  
 Here we proposed that Smad4-R361-mutant loses its tumor suppressive arm and 
retains binding to LEF1, resulting in enhanced WNT signaling. Although we have 
described this event in detail in this thesis, we still do not know exactly how this is 
occurring.  
  Firstly, we can speculate that the inability of Smad4mut to bind to Smad2/3 
following TGF-β treatment increases the pool of available mutSmad4 to bind to LEF1. This 
would redirect Smad4mut to upregulate WNT signaling, while Smad4 wild-type regulates 
TGF-β and WNT signaling simultaneously. A possible way that we could test this 
hypothesis is to determine the effect of TGF-β signaling on WNT signaling in CRC cell 
lines. To test this, we could perform the  TOP/FOP assay on the HCT116 3:6 cells and 
treat the cells with either the TGF-β soluble ligand or a TGFβ receptor kinase 
(ALK5/TGFβRI) inhibitor SB431542167. If our redirection hypothesis is true, we would 
expect that blocking TGF-β signaling would increase WNT signaling in our CRC cells 
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expressing both mutant and wild-type Smad4. However, there is a possibility that inhibition 
of TGF-β signaling will reduce WNT signaling, suggesting that the two pathways are 
working together. If this is our result, a way to possibly explain this would be through 
inhibitor Smad, Smad7, which is a downstream target gene of TGF-β signaling. In the 
cytoplasm, Smad7 is one of the points that link the two pathways. It is well known that 
Smad7 functions to compete with Smad2/3 for receptors, which leads to ubiquitination and 
degradation of receptors and hence inhibiting Smad2/3 phosphorylation and activation38. 
However, Smad7 has been found to disassemble the β-catenin destruction complex by 
binding to AXIN, thus stabilizing β-catenin and promoting its nuclear translocation168. 
When we treat parental HCT116 3:6 cells with TGF-β ligand, we have seen an 
upregulation of SMAD7 transcript (data not shown). Given that Smad7 is upregulated in 
the presence of TGF-β signaling, and Smad7 has been shown to regulate WNT signaling; 
it would make sense that inhibiting TGF-β could also result in downregulation of WNT 
signaling.   
 In addition, a recent study by Voorneveld et al claims that BMP can affect WNT 
signaling depending on both SMAD4 and p53 status. In the normal colonic epithelium, the 
BMP pathway counteracts WNT signaling pathway in order to maintain tissue 
homeostasis169.  In their study, they found that wild-type p53 is necessary for BMP to 
inhibit WNT signaling and loss of Smad4 completely reverses the BMP-WNT interaction, 
switching from inhibition to activation164. This is the opposite of what we see in CRC cells, 
as presence of Smad4 wild-type protein actually enhances WNT signaling compared to 
empty vector cells (expressing wild-type p53). Nevertheless, it would be interesting to 
explore a BMP-SMAD4-WNT axis to help us better understand the effects of Smad4 
mutations on WNT signaling. If somehow BMP signaling is redirecting Smad4 to enhance 
WNT signaling, we could test this theory by using a similar experimental setup as 
proposed above. We would use our CRC cell lines and either treat with BMP ligand or 
   
 
  52 
 
inhibit BMP signaling using an inhibitor (LDN-193189)170, followed by a TOP/FOP 
luciferase assay to measure downstream WNT signaling. In general, understanding the 
molecular mechanisms of how Smad4mut is able to upregulate WNT signaling compared 
to wild-type Smad4 in colorectal cancer cells would further validate our findings stated in 
this body of work.  
 
Uncovering Smad4 mutant phenotype in vitro and in vivo  
 Here, we presented evidence that mut-Smad4 is unable to promote canonical 
downstream TGF-β signaling (Figures 7 & 8). Although the work done in this thesis sheds 
light on the more novel role of Smad4 in colorectal cancer, understanding the phenotype 
of Smad4 mutations both in vivo and in vivo would provide invaluable information on 
Smad4mut functions in tissues.  
TGF-β controls cell growth by activating cyclin dependent kinase inhibitors (CDKIs) 
such as p21 and p15 resulting in growth inhibition. Previous studies have demonstrated 
that TGF-β growth inhibition is dependent on the presence of Smad4171. In addition, 
restoration of Smad4-WT in both human and murine CRC cell lines restores TGF-β 
induced growth inhibition and reduces migration and invasion172. This, along the data 
presented in this thesis, would lead us to hypothesize that colorectal cancer cells 
expressing Smad4 mutants will exhibit higher tumorigenicity, migration, and invasion 
compared to their wild-type counterpart.  
To determine the role of Smad4 mutations in CRC malignancy, we would use our 
SW480, SW620 and HCT116 3:6 cells and perform WST-1 and BrdU incorporation 
proliferation assays in the absence or presence of soluble TGF-β ligand. As a control, we 
could treat cells with TGF-β receptor kinase (ALK5/TGFβRI) inhibitor SB431542167, which 
would abrogate TGF-β signaling by blocking the receptor. We have some preliminary data 
looking at cell migration and invasion in HCT116 3:6 cells (Fig 13A & B). HCT116 3:6 cells 
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expressing Smad4-R361 mutation seem to have an intermediate migratory and invasive 
phenotype compared to Smad4-null and Smad4-WT cells. In order to complement this 
experiment, we could also perform a cell migration assay (in vitro wound healing assay). 
As mentioned in the introduction to this thesis, TGF-β can induce epithelial to 
mesenchymal transition (EMT) by inducing expression of EMT-promoting factors like 
Snail, Slug, ZEB and Twist70. As EMT has been shown to be dependent on the presence 
of Smad4173, we could look into the effect of Smad4-mutant on inducing these EMT 
transcription factors. Investigating the details of how Smad4-mut expression is driving 
epithelial-mesenchymal transition can help us better understand the role in EMT and 
identifying how to prevent Smad4-mut from promoting this event in cancer patients.  
Patients with mutant Smad4 have worse overall survival than patients with wild-
type Smad4143. Our lab, as well as others, have extensively shown that downregulation of 
Smad4-WT through shRNA leads to a higher incidence of primary tumors and metastasis 
to the liver in mice81,83. Because all of the experiments proposed have been in vitro, we 
could look into how these Smad4-mut phenotypes translate in an in vivo mouse model. 
As orthotopic models accurately represent the progression and metastasis of CRC, we 
could use an orthotopic cecal injection to evaluate the effect of Smad4 mutations on CRC 
tumorigenicity and liver metastasis. Incidence of primary tumor formation would be 
assessed by looking at the colon, while incidence of metastasis would be assessed by 
looking in the liver. Taken together, these studies would allow us to understand whether 
Smad4-mut promote CRC progression and whether it would make sense to block Smad4-
mut function in colorectal cancer patients. 
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Figure 13. R361-mutant attenuates the inhibitor effect of Smad4 on cell migration 
and invasion in HCT116 3:6 cells. The imagines of HCT116 3:6 cells are representative 
of one pilot experiment (magnification 40X). Migration (A) and invasion (B) were 
determined using transwell assays. The result of the quantification of cell migration and 
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Effects of Smad4 mutations on other pathways in the TGF-β superfamily  
  As previously mentioned, TGF-β can activate both Smad and non-Smad signaling 
pathways, such as Erk, JNK, and p38 MAPK kinase pathways39. Mehrvarz Sarshekeh et 
al’s study revealed that patients with advanced disease observed a markedly shorter 
progression-free survival time in patients with SMAD4-mutated tumors than in those wild-
type for SMAD4 when treated with anti-epidermal growth factor receptor (EGFR) 
treatment143. The fact that EGFR like cetuximab and panitumumab27,28 is provided to 
patients with wild-type KRAS (as any alterations in can lead to constitutive activation of 
EGFR and ultimately to drug resistance28) suggests that mut-Smad4 may be affecting 
other signaling pathways besides TGF-β. 
To test this, we would need to use cell lines with wild type KRAS so that constitutive 
active signaling of the pathway does not interfere with the interpretation of our results. The 
tools to explore this, however, are limited given that most CRC cell lines harbor mutations 
in KRAS gene (a reflection of patient data, where over half of CRC patients harbor 
mutations in KRAS). There is one cell lines we could work with (COLO-320) that has wild-
type KRAS and BRAF and baseline PI3K signaling. However, these cell lines express 
endogenous Smad4 protein. We would need to 1) generate COLO-320 isogenic cell lines 
using CRISPR-Cas9 to generate Smad4 KO clones and 2) re-introduce Smad4 retrovirally 
(as we did in HCT116 3:6 cells). Due to the limitation of cell lines, we could also use an 
organoid model system. By introducing inactivating mutations in APC, p53 and SMAD4 
and activating KRAS(G12D) mutation, scientists have been able to use intestinal stem 
cells to better model colorectal cancer in vitro and in vivo 174,175. In our case, we could use 
this system to generate p53, APC and SMAD4 null organoids via CRISPR-Cas9, then 
later introduce our Smad4 via retrovirus. As loss of SMAD4 has been shown to activate 
downstream Akt and Erk signaling141,166,176, we can measure the levels of p-AKT and p-
ERK in both Smad4-mut expressing cell lines and organoids. Overall, these observations 
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would allow us to understand the effect of Smad4 R361-mutations on both other signaling 
pathways in the TGF-β superfamily.   
 
Investigating the mutSmad4-LEF1 axis in other cancers & diseases  
 It is worth investigating the mutSmad4-LEF1 signaling axis in other cancers, to 
confirm the mechanism we have uncovered is conserved among other tumor types. This 
will help us better understand how WNT signaling pathway could be used as a therapeutic 
option for patients who have abnormalities in this pathway.  
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers 
with a five-year survival of less than 5%87. Despite advancements in treatment and 
therapies, mortality rates for PDAC patients still remains high. Over half of PDAC patients 
with invasive disease have alterations in Smad4 protein177, including deep deletions and 
missense mutations. Studies have shown that loss or inactivation of SMAD4 is associated 
with poor prognosis, due to an increased incidence of metastatic disease178. In addition, 
SMAD4 inactivating mutations occur in approximately 20% of all pancreatic cancer92. 
Similar to CRC tumors, they can occur in either MH1 or the MH2 domain, with the latter 
resulting in either loss of protein stability or disruption of dimerization ability of the Smads. 
One study has shown that missense mutations in SMAD4 at Y353C residue attenuates 
the inhibitory effect of SMAD4 on cell migration and invasion in PDAC cells without 
affecting cell proliferation179. This suggests that missense mutations in Smad4 could affect 
PDAC progression, just as we expect them to affect CRC progression.  
According to cbioportal data, mutations in the R361 residue also are the most 
frequent type of Smad4 missense mutation found in PDAC patients, as evidenced by their 
lollipop plots (Figure 14A). In conclusion, understanding what the effect of R361-mutations 
on PDAC patients are, and the mechanism whereby they can affect PDAC progression 
can provide a firmer empirical basis for PDAC treatment. 
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Apart from cancers, it would also be interesting to understand the role of mutant 
Smad4 (and Smad4mut-LEF1 axis) in other diseases such as juvenile polyposis syndrome 
(JPS). Juvenile polyposis syndrome (JPS) is an autosomal disease that is characterized 
by the presence of benign polyps in the gastrointestinal tract, most commonly in the colon. 
Patients with JPS have up to a 50% risk of developing specific types of cancer, including 
colorectal (CRC) and other gastrointestinal (GI) malignancies180,181. Similarly, familial 
adenomatous polyposis (FAP) is a familial cancer predisposition syndrome with risk of 
multiple cancer types, including 100% risk of colon cancer absent intervention. The 
genetic basis of FAP is well-understood to be related to loss-of-function mutations, 
deletions, or duplications in the APC gene, known to hyperactivate the WNT pathway182 
This in turn leads to overexpression of the MYC oncogene and enhanced cell 
proliferation183.  
However, WNT pathway mutations have not been described in JPS. Instead, 30-
40% of JPS cases are associated with germline frameshift and missense mutations in 
SMAD4 and BMPRIA receptor184.  In CRC, SMAD4 pathway mutations (found with 10-
35% frequency) are known to be associated with such “late” events. However, how 
SMAD4 mutations can contribute to polyp formation and increased cancer risk in JPS 
patients remains unknown. Based on the work that we have done in our CRC cell lines, 
we would hypothesize that germline SMAD4 missense mutations in JPS could promote 
polyp formation by increasing WNT signaling. To test this, we would use CRISPR-Cas9 
technology to knockout endogenous Smad4 in normal colon organoids and immortalized 
colonocyte cell lines (NCM460, NCM365). We would then reconstitute them with naturally 
occurring SMAD4 JPS variants (focusing on Smad4-R361H/C mutations) using 
retroviral/lentiviral transduction. Once the JPS-associated Smad4 mutants (e.g., 
R361H/CS) are stably expressed, we would measure changes in WNT signaling by using 
WNT-reporter activity assay (TOP/FOP luciferase). In addition, we could also test for 
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different downstream signaling events correlated with WNT, such as activation of WNT 
target genes like Axin2 and β-catenin and enhanced cell proliferation. Finally, we can 
perform RNA-Seq on SMAD4-WT and SMAD4-mut cell lines and organoid, to compare 
and contrast their transcriptomes. Because we would that expect that the presence of 
SMAD4 missense mutations would correlate with enhanced reliance on this signaling 
pathway, it would also be interesting to test the responses of patient derived organoids 
and JPS-model cell lines with existing WNT inhibitors such as PRI-724 and ICG-001. Our 
hypothesis is that mutations in Smad4 results in hyperactivation of WNT signaling, which 
could provide direct molecular targets for therapeutic intervention. Identification of such 





Figure 14. R361 mutation is prevalent in Smad4 in PDAC. (A) The prevalence and 
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Identification of other proteins that might interact with mutSmad4 
Protein-protein interactions are essential to the function of all proteins and define 
their biological roles. Therefore, identification of protein binding partners can bring to light 
important information about protein functions. One of the most practical and high-yielding 
approaches is immunoprecipitation of a bait protein followed by mass spectrometry to 
identify co-precipitating proteins. This technique has been done to identify novel binding 
partners for mutations in other tumor suppressor genes, for example TP53. Some studies 
have used mass spectrometry to demonstrate that mutant p53, but not p53 wild type, are 
able to bind to novel proteins. For example, p53 R175H is able to bind to proteins Tim50 
and MCM7185 and p53 R273H can bind NRD1 specifically186 . Thus, this method could be 
useful in identifying novel protein-protein interactions or targets of mutant Smad4 as well.  
Although proteomics analysis has been done in CRC cells with either Smad4-null 
and Smad4 wild-type expressing cells187, no such experiments have been done with cells 
expressing mutSmad4. To begin to investigate this, we could analyze the difference in 
protein binding between wild-type Smad4 and mutant Smad4 via mass spectrometry 
analysis. Because alteration at a single residue affects the binding of Smad4 to R-Smads, 
it would be interesting to know it this mutation allows for other (yet unidentified) proteins 
to bind to mutSmad4. If we wanted to further continue to study the role of mutSmad4 on 
WNT signaling, we could do an alternate version of the experiment. We could pretreat the 
cells with a WNT inhibitor and then send samples to mass spectrometry to identify proteins 
that might bind differently to mutSmad4 in a WNT dependent manner. Once candidates 
have been identified, we could test how the interaction of mutSmad4, and other proteins 
affect either WNT signaling or any other signaling pathway that we choose to continue to 
study. We could also test how the binding of these candidate proteins to mutSmad4 affects 
their phenotype both in vitro and in vivo, which could help us further define on why 
mutSmad4 (specifically R361 mutation) is so highly selected for in CRC cancer patients.  
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SUMMARY AND CONCLUDING REMARKS  
The work presented here demonstrated a novel, previously unidentified, function 
for mutant Smad4 in CRC cells. We show that hotspot missense mutation in Smad4, 
R361H/C is unable to bind to R-Smads, Smad2/3 or accumulate in the nucleus following 
TGF-β treatment. In addition, Smad4-R361 mutants lose the ability to activate canonical 
downstream TGF-β signaling. Although initially these R361 mutations seemed to behave 
like loss of function mutations, we wanted to continue studying them given that they are 
so highly selected for in CRC tumors, which is more consistent with a gain-of- or 
neomorphic function. Following RNA-Sequencing, we were surprised to see that R361H 
has a gene signature associated with upregulation of the TCF/LEF protein complex and 
boosts downstream WNT signaling.  
Having established that there is a gain of function role for Smad4 mutants, this 
information can be used to develop peptide-based inhibitors targeting the interacting 
domains between mutSmad4-LEF1, opening a therapeutic window for CRC patients 
harboring Smad4-R361 mutations.  
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